Options when MCC has spread, including avelumab and pembrolizumab
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
"Advanced" Merkel cell carcinoma (MCC) means disease that cannot be cured with surgery and radiation alone — most often because it has spread to distant lymph nodes or organs (metastatic, Stage IV), or because it keeps recurring locally. A decade ago the main option was chemotherapy, which shrank tumors briefly but rarely held them. Immune checkpoint inhibitors changed that, and they are now the standard first treatment.
This guide explains why MCC responds so well to immunotherapy, which drugs are used, what to expect, and what the options are if immunotherapy is not enough or not possible.
Both routes to MCC give the immune system a target. Virus-positive tumors carry foreign viral proteins; UV-driven tumors carry a very high number of mutations that create abnormal proteins. In both cases, tumors often try to hide by displaying a molecule called PD-L1, which switches off attacking T cells. Checkpoint inhibitors block that off-switch (the PD-1/PD-L1 pathway), letting the immune system see and destroy the cancer.
The practical result: response rates of roughly 50–65% in trials, and — unlike chemotherapy — responses that frequently last for years.
A PD-L1 inhibitor and the first drug approved specifically for metastatic MCC, based on the JAVELIN Merkel 200 trial in patients whose disease had progressed after chemotherapy. Later data supported its use as a first-line treatment as well. Given as an intravenous infusion, typically every two weeks.
A PD-1 inhibitor studied as first-line therapy for advanced MCC, with durable responses and encouraging overall survival reported in a multicenter trial. Given as an infusion every three to six weeks.
Nivolumab (another PD-1 inhibitor) has activity in MCC and is used in some settings, including before surgery in trials. Combinations of a PD-1 inhibitor with a CTLA-4 inhibitor, and newer agents, are under active study.
Treatment is an outpatient infusion continued as long as it works and is tolerated. Scans every couple of months track the response. Because these drugs take the brakes off the immune system, they can cause it to inflame healthy organs — so-called immune-related adverse events:
Most of these are controllable when treated early, often by pausing the drug and giving corticosteroids. Report any new symptom promptly rather than waiting for the next visit — timing is what keeps side effects manageable.
People who are immunosuppressed — including organ transplant recipients — need an individualized plan, since checkpoint inhibitors can cause graft rejection or may be less effective when immune function is impaired.
For advanced or metastatic MCC, checkpoint immunotherapy — avelumab, pembrolizumab, or nivolumab — is the standard first choice, and for a substantial share of patients it produces responses that last for years. Radiation, surgery for isolated spots, chemotherapy, and clinical trials round out the options.
Care at a center experienced in MCC and in managing immune-related side effects gives you the best chance of benefiting from these treatments safely. Ongoing monitoring continues throughout.
Disclaimer: Educational only. Not a substitute for professional medical advice. Always consult your dermatologist or oncologist about your personal diagnosis and treatment plan.
Chat with our AI guide for personalized information about Merkel cell carcinoma
Chat with the Navigator